EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
Experts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
EP: 1.In-Clinic Educational Resource on the OAB Treatment Pathway
EP: 2.EP. 1: An Introduction of the Speakers
EP: 3.EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations
EP: 4.Ep. 3: The Typical Patient with OAB and Common Signs and Symptoms
EP: 5.EP. 4: The Role of Urodynamic Testing in OAB Evaluation
EP: 6.EP. 5: OAB Treatment: Available Strategies and Rationale for Use
EP: 7.EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB
EP: 8.Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies
EP: 9.EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB
EP: 10.EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB
EP: 11.EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making
EP: 12.EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies
EP: 13.EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting
EP: 14.EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA
EP: 15.EP. 14: SNM and PTNS for OAB: Device Management and Followup
EP: 16.EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Multicomponent intervention boosts quality of life in overactive bladder patients
March 15th 2024A recent study reveals the efficacy of a cognitive behavior therapy program, showcasing significant improvements in health-related quality of life among women grappling with moderate to severe overactive bladder.
Read More
Optimizing pain management post urogynecologic surgery with restrictive opioid protocol
March 14th 2024A recent study suggests that restrictive opioid prescribing protocols post-urogynecologic surgery are as effective as standard protocols, emphasizing the importance of multimodal analgesia and outpatient follow-up for patient satisfaction.
Read More
Study finds no increased stress urinary incontinence recurrence risk from childbirth
March 11th 2024A recent meta-analysis challenged common clinical assumptions, finding no increased risk of stress urinary incontinence recurrence or need for reoperation after subsequent pregnancy and childbirth following a midurethral sling procedure.
Read More
Cefepime–Taniborbactam outperforms meropenem in treating complicated UTI
February 15th 2024A recent study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.
Read More
